PYXS Valuation
Pyxis Oncology Inc
$
1.230
- Overview
- Forecast
- Valuation
- Earnings
PYXS Relative Valuation
PYXS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PYXS is overvalued; if below, it's undervalued.
Historical Valuation
Pyxis Oncology Inc (PYXS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.89. The fair price of Pyxis Oncology Inc (PYXS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.23
Fair
-0.88
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Pyxis Oncology Inc. (PYXS) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.19. The thresholds are as follows: Strongly Undervalued below -3.49, Undervalued between -3.49 and -1.84, Fairly Valued between 1.46 and -1.84, Overvalued between 1.46 and 3.11, and Strongly Overvalued above 3.11. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.01
EV/EBIT
Pyxis Oncology Inc. (PYXS) has a current EV/EBIT of -0.01. The 5-year average EV/EBIT is -0.31. The thresholds are as follows: Strongly Undervalued below -4.02, Undervalued between -4.02 and -2.16, Fairly Valued between 1.54 and -2.16, Overvalued between 1.54 and 3.39, and Strongly Overvalued above 3.39. The current Forward EV/EBIT of -0.01 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Pyxis Oncology Inc. (PYXS) has a current PS of 0.00. The 5-year average PS is 73.45. The thresholds are as follows: Strongly Undervalued below -239.67, Undervalued between -239.67 and -83.11, Fairly Valued between 230.01 and -83.11, Overvalued between 230.01 and 386.57, and Strongly Overvalued above 386.57. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.19
P/OCF
Pyxis Oncology Inc. (PYXS) has a current P/OCF of -1.19. The 5-year average P/OCF is -2.36. The thresholds are as follows: Strongly Undervalued below -6.51, Undervalued between -6.51 and -4.44, Fairly Valued between -0.29 and -4.44, Overvalued between -0.29 and 1.79, and Strongly Overvalued above 1.79. The current Forward P/OCF of -1.19 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Pyxis Oncology Inc. (PYXS) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.73. The thresholds are as follows: Strongly Undervalued below -4.79, Undervalued between -4.79 and -3.26, Fairly Valued between -0.19 and -3.26, Overvalued between -0.19 and 1.34, and Strongly Overvalued above 1.34. The current Forward P/FCF of 0.00 falls within the Overvalued range.
Pyxis Oncology Inc (PYXS) has a current Price-to-Book (P/B) ratio of 0.74. Compared to its 3-year average P/B ratio of 0.79 , the current P/B ratio is approximately -6.68% higher. Relative to its 5-year average P/B ratio of 0.69, the current P/B ratio is about 6.57% higher. Pyxis Oncology Inc (PYXS) has a Forward Free Cash Flow (FCF) yield of approximately -84.99%. Compared to its 3-year average FCF yield of -83.70%, the current FCF yield is approximately 1.55% lower. Relative to its 5-year average FCF yield of -73.01% , the current FCF yield is about 16.41% lower.
0.74
P/B
Median3y
0.79
Median5y
0.69
-84.99
FCF Yield
Median3y
-83.70
Median5y
-73.01
Competitors Valuation Multiple
The average P/S ratio for PYXS's competitors is -1.73, providing a benchmark for relative valuation. Pyxis Oncology Inc Corp (PYXS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PYXS decreased by 67.55% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 2.82M.
The secondary factor is the Margin Expansion, contributed 411.19%to the performance.
Overall, the performance of PYXS in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FSK
FS KKR Capital Corp
17.490
USD
-0.85%
ENVX
Enovix Corp
10.210
USD
-2.76%
MNDY
monday.com Ltd
175.740
USD
-0.67%
IDXX
IDEXX Laboratories Inc
650.840
USD
-0.48%
QS
Quantumscape Corp
9.030
USD
-0.66%
OCGN
Ocugen Inc
1.050
USD
+1.94%
PTON
Peloton Interactive Inc
8.520
USD
+0.35%
MYO
Myomo Inc
0.975
USD
-0.51%
TTD
Trade Desk Inc
52.120
USD
+2.68%
LYFT
Lyft Inc
15.820
USD
+8.21%
FAQ
Is Pyxis Oncology Inc (PYXS) currently overvalued or undervalued?
Pyxis Oncology Inc (PYXS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.89. The fair price of Pyxis Oncology Inc (PYXS) is between NaN to NaN according to relative valuation methord.
What is Pyxis Oncology Inc (PYXS) fair value?
How does PYXS's valuation metrics compare to the industry average?
What is the current P/B ratio for Pyxis Oncology Inc (PYXS) as of Aug 18 2025?
What is the current FCF Yield for Pyxis Oncology Inc (PYXS) as of Aug 18 2025?
What is the current Forward P/E ratio for Pyxis Oncology Inc (PYXS) as of Aug 18 2025?